CORC

在结果中检索

CORC

浏览/检索结果: 共16条，第1-10条 帮助

限定条件    
已选(0)清除 条数/页：   排序方式：
Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer 期刊论文
EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 卷号: 110, 页码: 51-61
作者:  Li, Xin;  Yang, Changyong;  Wan, Hong;  Zhang, Ge;  Feng, Jun
收藏  |  浏览/下载：136/0  |  提交时间：2019/01/08
Afatinib Dose Adjustment: Effect on Safety, Efficacy and Patient-Reported Outcomes in the LUX-Lung 3/6 Trials in EGFRm plus NSCLC 期刊论文
JOURNAL OF THORACIC ONCOLOGY, 2017, 卷号: 12, 期号: 11
作者:  Hirsh, V.;  Tan, E.;  Wu, Y.;  Sequist, L.;  Zhou, C.
收藏  |  浏览/下载：7/0  |  提交时间：2019/12/04
Analysis of long-term response to first-line afatinib in the LUX-Lung 3, 6 and 7 trials in advanced EGFRm+ NSCLC 期刊论文
Journal of Thoracic Oncology, 2017, 卷号: 12
作者:  null
收藏  |  浏览/下载：3/0  |  提交时间：2019/12/04
Impact of ErbB Mutations on Clinical Outcomes in Afatinib- or Erlotinib-Treated Patients with SCC of the Lung 期刊论文
JOURNAL OF THORACIC ONCOLOGY, 2017, 卷号: 12, 期号: 11
作者:  Goss, G.;  Felip, E.;  Cobo, M.;  Lu, S.;  Syrigos, K.
收藏  |  浏览/下载：9/0  |  提交时间：2019/12/05
Second-line afatinib vs erlotinib for patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8 [LL8]): analysis of tumour and serum biomarkers and long-term responders 会议论文
作者:  Li, W.;  Gadgeel, S. M.;  Soria, J. C.;  Felip, E.;  Cobo, M.
收藏  |  浏览/下载：6/0  |  提交时间：2019/12/05
Second-line afatinib vs erlotinib for patients with squamous cell carcinoma (SCC) of the lung (LUX-Lung 8 [LL8]): analysis of tumour and serum biomarkers and long-term responders 期刊论文
EUROPEAN JOURNAL OF CANCER, 2017, 卷号: 72
作者:  Goss, G.;  Cobo, M.;  Lu, S.;  Soria, J. C.;  Syrigos, K.
收藏  |  浏览/下载：11/0  |  提交时间：2019/12/05
Second-Line Afatinib versus Erlotinib for Patients with Squamous Cell Carcinoma of the Lung (LUX-Lung 8): Analysis of Tumor and Serum Biomarkers 会议论文
作者:  Isla, Dolores;  Min, Young Joo;  Ardizzoni, Andrea;  Gadgeel, Shirish;  Dupuis, Nicholas
收藏  |  浏览/下载：11/0  |  提交时间：2019/12/05
EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6 期刊论文
BRITISH JOURNAL OF CANCER, 2017, 卷号: 116, 期号: 2
作者:  Wu, Yi-Long;  Sequist, Lecia V.;  Hu, Cheng-Ping;  Feng, Jifeng;  Lu, Shun
收藏  |  浏览/下载：5/0  |  提交时间：2019/12/05
Blocking autophagy improves the anti-tumor activity of afatinib in lung adenocarcinoma with activating EGFR mutations in vitro and in vivo 期刊论文
SCIENTIFIC REPORTS, 2017, 卷号: 7
作者:  Hu, Xiangxiang;  Shi, Si;  Wang, Huan;  Yu, Xiaochen;  Wang, Qian
收藏  |  浏览/下载：11/0  |  提交时间：2019/12/05
A Phase IIIb Open-Label, Single-Arm Study of Afatinib in EGFR TKI-Naive Patients with EGFRm plus NSCLC: An Interim Analysis 会议论文
作者:  Wu, Y.;  Tu, H.;  Feng, J.;  Shi, M.;  Zhao, J.
收藏  |  浏览/下载：6/0  |  提交时间：2019/12/05
afatinib  EGFR  NSCLC  

©版权所有 ©2017 CSpace - Powered by CSpace